Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Current atherosclerosis reports

Volumn 15, Issue 5, 2013, Pages

  Medford, Russell M ^a   Dagi, T Forcht ^b   Rosenson, Robert S ^b   Offermann, Margaret K ^b  

^a The Salutramed Group Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; ECONOMICS; HUMAN; NEOPLASM; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 84883686055     PISSN: None     EISSN: 15346242     Source Type: None    
DOI: 10.1007/s11883-013-0321-0     Document Type: Review

References (0)